

O I P E P21324.A02

JC03 Rec'd PCT/PTO

10 DEC 2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

DEC 10 2001
PATENT & TRADEMARK OFFICE

Applicant : Tadao OHNO et al.

Serial No : 09/890,266 (National Stage of PCT/JP00/00692)

Filed : August 8, 2001 (International Filing Date February 9, 2000)

For : TUMOR VACCINE

INFORMATION DISCLOSURE STATEMENT

Commissioner of Patents and Trademarks
Washington, D.C. 20231

Sir:

In accordance with 37 C.F.R. §§ 1.56, 1.97 and 1.98, Applicants hereby bring the following information to the attention of the Examiner in charge of the above-identified application:

Pardoll, D.M., Nature Med., 4 (5Suppl.), pp 525-531 (1998) is cited and discussed in the specification beginning at page 1, line 15.

Nestle, F.O., et al., Nature Med., 4, pp 328-332 (1998) is cited and discussed in the specification beginning at page 1, line 21.

Nakanishi, T., et al., Biochem. Biophys. Res. Comm., 250, pp. 793-797 (1997) is cited and discussed in the specification beginning at page 1, line 25.

Rosenberg, S.A., et al., Nature Med., 4, pp 321-327 (1998) is cited and discussed in the specification beginning at page 2, line 3.

Golumbeck, P.T., et al., Cancer Res., 53, pp. 5841-5844 (1993) is cited and discussed in the specification beginning at page 2, line 5.

P21324.A02

Naito, M. and Seno, S., Cell Biol. International Rep., 5, pp. 675-681 (1981) is cited and discussed in the specification beginning at page 3, line 5.

Liu, S.Q., et al., Nature Med., 2, pp. 1283-1283 (1996) is cited and discussed in the specification beginning at page 4, line 1.

Falo, Jr., L.D., et al., Nature Med., 1, pp 649-653 (1996) is cited and discussed in the specification beginning at page 4, line 10.

Kim, C., et al., Cancer Immunol. Immunother., 47, pp. 90-96 (1998) is cited and discussed in the specification at page 4, line 15.

Inaba, et al., Lecture SI-3-3, Japanese Immunology Society, Dec. 2, 1998, is cited and discussed in the specification at page 4, line 19.

Guo, Y.J., et al., Nature Med., 3, pp. 451-455 (1997) is cited and discussed in the specification at page 11, line 16.

Levitsky, H.I., et al., J. Immunol., 156, pp. 3858-3865 (1996) is cited and discussed in the specification at page 24, line 7.

Copies of the above-noted documents are enclosed together with a duly completed form PTO-1449. The Examiner is accordingly requested to consider each of these documents, and to make them of record in this application by initialing in the appropriate spaces on the Form PTO-1449. Applicant respectfully requests that the Examiner include a copy of the initialed Form PTO-1449 with the next communication from the U.S. Patent and Trademark Office.

Applicants note that an Office Action on the Merits has not issued in the instant application. However, if an Office Action on the Merits has issued, and is crossing this statement in the mail, the undersigned hereby authorizes the Commissioner to charge any fee necessary for consideration of


P21324.A02

this statement, including any payment under 37 C.F.R. 1.17(p), to be charged to Applicant's Deposit Account No. 19-0089.

Should the Examiner have any questions or comments regarding this matter, the undersigned may be contacted at the below-listed telephone number.

December 10, 2001
GREENBLUM & BERNSTEIN, P.L.C.
1941 Roland Clarke Place
Reston, VA 20191
(703) 716-1191

Respectfully submitted,
Tadao OHNO et al.


Bruce H. Bernstein
Reg. No. 29,027
36,086

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office		Atty. Docket No. P1324	Serial No. 09/890,266	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				Applicant Tadao OHNO et al.		
				Filing Date August 8, 2001	Group Unknown	
U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS						
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)						
	1	Pardoll, D.M., Nature Med., 4 (5Suppl.), pp 525-531 (1998).				
	2	Nestle, F.O., et al., Nature Med., 4, pp 328-332 (1998).				
	3	Nakanishi, T., et al., Biochem. Biophys. Res. Comm., 250, pp. 793-797 (1997).				
	4	Rosenberg, S.A., et al., Nature Med., 4, pp 321-327 (1998).				
	5	Golumbeck, P.T., et al., Cancer Res., 53, pp. 5841-5844 (1993).				
	6	Naito, M. and Seno, S., Cell Biol. International Rep., 5, pp. 675-681 (1981).				
	7	Liu, S.Q., et al., Nature Med., 2, pp. 1283-1283 (1996).				
	8	Falo, Jr., L.D., et al., Nature Med., 1, pp 649-653 (1996).				
	9	Kim, C., et al., Cancer Immunol. Immunother., 47, pp. 90-96 (1998).				
	1 0	Inaba, et al., Lecture SI-3-3, Japanese Immunology Society, Dec. 2, 1998.				
	1 1	Guo, Y.J., et al., Nature Med., 3, pp. 451-455 (1997).				
	1 2	Levitsky, H.I., et al., J. Immunol., 156, pp. 3858-3865 (1996).				
EXAMINER			DATE CONSIDERED			
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.						